Black Health
Inhaled corticosteroid + long-acting beta-2 agonist (ICS + LABA) Asthma (including SMART) COPD

Budesonide/Formoterol (Symbicort, Breyna) and Black patients

Brand names: Symbicort, Breyna

Last reviewed: Sources checked:

What Budesonide/Formoterol does

Symbicort combines budesonide (ICS) and formoterol (LABA). Formoterol has a rapid onset of action (5–15 minutes) unlike salmeterol, enabling its use as both a controller and a reliever — the SMART (single maintenance and reliever therapy) approach endorsed by GINA and NAEPP 2020.

What the evidence says for Black patients

Symbicort SMART has several advantages relevant to Black patients with asthma:

  • Lower total beta-agonist exposure. SMART therapy reduces total SABA use compared to conventional 'ICS + albuterol rescue' regimens. For Black patients with the ADRB2 Arg16Arg genotype, reducing beta-agonist exposure is theoretically beneficial.
  • Real-world effectiveness. The NOVEL START study (Hardy et al., Lancet 2019;394:919–28, PMID 31451207) and SYGMA trials confirmed SMART equivalent or superior to daily ICS plus rescue albuterol.
  • The BARD pediatric finding (see Advair page) suggests that for Black children, doubling the ICS dose outperforms adding a LABA — so SMART in children should be chosen carefully, not reflexively.
  • Generic budesonide/formoterol (Breyna) launched in 2022, easing cost barriers.

Common alternatives

Advair (fluticasone/salmeterol) — salmeterol has slower onset, so not suitable for SMART. Breo (once-daily). Mometasone/formoterol (Dulera).

Side effects

  • Oral candidiasis
  • Hoarseness
  • Tremor, tachycardia
  • Pneumonia in COPD
  • Adrenal suppression at high ICS doses

Factors that affect adherence

For SMART use, patients must understand they use the same inhaler for daily control AND for symptom relief — a frequent source of confusion. Generic Breyna is now widely available.

Questions to ask your doctor

Bring this list to your next appointment.

  • Am I doing SMART — using the same inhaler for both control and relief — or a separate-albuterol-rescue plan?
  • Does generic Breyna work for my insurance?
  • If I have a Black child with asthma, are we considering doubling the ICS before LABA based on BARD?

References

  1. Hardy J, Baggott C, Fingleton J, et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (NOVEL START). Lancet. 2019;394:919–928. PMID 31451207.
  2. O'Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled combined budesonide-formoterol as needed in mild asthma (SYGMA 1). NEJM. 2018;378:1865–1876.
  3. Wechsler ME, et al. BARD trial. NEJM. 2019;381:1227–1239.
  4. U.S. Food and Drug Administration. Symbicort (budesonide/formoterol) label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021929s057lbl.pdf

Medical disclaimer

This page is patient education, not prescribing guidance. It summarizes the published evidence about how this medication has been studied in Black patients — it is not a substitute for the judgment of your personal clinician. Never start, stop, or change a prescription based on something you read here. If you have questions about your medication, call your prescriber or pharmacist. For emergencies, call 911.

Read our editorial standards for how we source, review, and update these pages.